首页> 外文期刊>Tropical Medicine and International Health: TM and IH >Subtype prevalence, plasmid profiles and growing fluoroquinolone resistance in Shigella from Kolkata, India (2001-2007): a hospital-based study.
【24h】

Subtype prevalence, plasmid profiles and growing fluoroquinolone resistance in Shigella from Kolkata, India (2001-2007): a hospital-based study.

机译:来自印度加尔各答的志贺氏菌的亚型患病率,质粒谱和对氟喹诺酮类药物的耐药性增长(2001-2007年):一项基于医院的研究。

获取原文
获取原文并翻译 | 示例
           

摘要

OBJECTIVES: Shigellosis is a major public health problem, and increasing antimicrobial resistance has complicated its treatment. We report isolation frequency, plasmid profiles and antimicrobial resistance of Shigella subtypes in Kolkata, India, from a prospective hospital-based study. METHODS: Fresh stool or rectal swabs were collected from children (<5 years) attending the Diarrhea Treatment Unit of a governmental paediatric referral hospital in Kolkata. Samples were processed following standard methods over a 7-year period from January 2001 to December 2007. RESULTS: Of 4478 samples collected, 516 (11.5%) were positive for Shigella spp. S. flexneri (312; 6.9%) was the most frequently isolated serogroup, ranking before S. sonnei (123, 2.7%), S. dysenteriae (48, 1.1%) and S. boydii (33, 0.7%). Although 10 subtypes of S. flexneri were identified, the common ones circulating locally were S. flexneri 2a (179), S. flexneri 6 (38) and S. flexneri 3a (36). Knowledge of Shigella subtypes is important for vaccine development. The majority of Shigella isolates (81.0%) were multidrug (two or more antimicrobial classes) resistant and showed high minimum inhibitory concentration (MIC) with commonly used drugs like ampicillin, tetracycline, co-trimoxazole and nalidixic acid. Emergence of fluoroquinolone (FQ)-resistant S. dysenteriae type 1 (100.0%) in 2002-2003 was followed by frequent isolation (>25.0%) of FQ-resistant S. flexneri 2a, and S. flexneri 3a in 2004, which restricted use of fluoroquinolones for treatment. A number of smaller plasmids (<20 kb) with distinct patterns have been observed for several years in predominant subtypes. CONCLUSION: Long-term surveillance of Shigellae and their antimicrobial resistance are mandatory in endemic areas to formulate treatment policy until any suitable candidate vaccine is available to control the disease.
机译:目的:志贺氏菌病是一个主要的公共卫生问题,抗菌药物耐药性的提高使其治疗变得复杂。我们从一项基于前瞻性医院的研究中报告了印度加尔各答的志贺氏菌亚型的分离频率,质粒概况和抗药性。方法:从加尔各答政府儿科转诊医院腹泻治疗科的儿童(<5岁)中收集新鲜的粪便或直肠拭子。在2001年1月至2007年12月的7年中,按照标准方法对样品进行了处理。结果:在所收集的4478个样品中,有516个(11.5%)的志贺氏菌属呈阳性。弗氏链球菌(312; 6.9%)是最常见的血清群,在索内链球菌(123,2.7%),痢疾链球菌(48,1.1%)和博伊氏链球菌(33,0.7%)之前排名。尽管确定了弗氏链球菌的10个亚型,但是局部循环的常见亚种是弗氏链球菌2a(179),弗氏链球菌6(38)和弗氏链球菌3a(36)。志贺氏菌亚型的知识对于疫苗开发很重要。大部分志贺氏菌分离株(81.0%)具有多药耐药性(两种或两种以上抗菌药),并且对常用药物如氨苄青霉素,四环素,复方新诺明和萘啶酸表现出较高的最低抑菌浓度(MIC)。耐氟喹诺酮(FQ)的痢疾链球菌1型(100.0%)在2002-2003年出现,随后在2004年频繁分离(> 25.0%)耐FQ的弗氏链球菌2a和弗氏链球菌3a,这限制了使用氟喹诺酮类药物治疗。多年以来,在主要的亚型中已观察到许多具有不同模式的较小质粒(<20 kb)。结论:在流行地区必须对志贺氏菌及其耐药性进行长期监测,以制定治疗策略,直到有合适的候选疫苗可控制该病为止。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号